The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium

M L Swahn, E. Johannisson, V. Daniore, B. de la Torre, M. Bygdeman
Human Reproduction · 1988 · vol. 3(7) , pp. 915–921 · doi:10.1093/oxfordjournals.humrep.a136809 · PMID:2846630 · W2255241594
Non-randomised trial OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-11 ⓘ

Administering RU486 on cycle days 7-10 prolonged the cycle by delaying ovulation, while mid-luteal phase treatment initiated bleeding in ovulating women without altering endometrial morphology.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Seventeen healthy women aged 24-45 years with regular menstrual periods, proven fertility and not using steroidal contraceptives or IUD were recruited for the study. The volunteers were followed during one control, one treatment and one follow-up cycle. Daily morning urine samples were obtained during the control and the treatment cycle. The samples were analysed with regard to pregnanediol glucuronide (P2-G), oestrone glucuronide (E1-G), oestradiol (E2), progesterone (P4), LH and creatinine. During the entire 3-month study the subjects kept a record of uterine bleeding and side effects. The subjects received 50 mg RU486 daily either on cycle days 7-10 (n = 7) or on cycle days 20-23 (n = 10). An endometrial biopsy was taken on cycle day 10 in the first group and on cycle days 21-28 in the second group of patients. Treatment during the proliferative phase caused significant prolongation of the cycle length due to a delay of the oestrogen and LH surge. However, once the oestrogen concentration started to increase, the remaining part of the cycle was normal. The length of the follow-up cycle was similar to that of the control cycle. The morphology of the endometrium did not differ from control samples taken from untreated women at the same time of the cycle. All ovulating women (n = 9) treated in the mid-luteal phase started to bleed on the 3rd to 4th day of the treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

My notes (saved in your browser only)

MeSH descriptors

Endometrium Estrenes Menstrual Cycle Menstruation Menstruation-Inducing Agents Adult Endometrium Estrenes Estrone Estrone Estrone Female Humans Hydrocortisone Hydrocortisone Luteinizing Hormone Luteinizing Hormone Menstrual Cycle Menstruation Menstruation-Inducing Agents

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

Cited by (10)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:19:54.474666+00:00
unpaywall
last seen: 2026-10-21T06:41:41.500114+00:00
License: CC0 · commercial use OK